Breaking News

Breaking news filtered in real-time to show only the most impactful headlines for US-listed public companies.

Twin Disc Announces Full Year and Fourth Quarter Results

MILWAUKEE, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Twin Disc, Inc. (NASDAQ: TWIN) today reported results for the fourth quarter and full fiscal year 2025 ended June 30, 2025.

Are there any significant changes in margins or segment performance that could affect the stock valuation? What guidance did Twin Disc issue for FY2026 and how might it influence market expectations? Did Twin Disc's Q4 revenue and earnings beat analyst consensus estimates?
Symbol: TWIN
Earnings
21 days ago
Read more globenewswire

Akebia Therapeutics and Innovative Renal Care Announce Nationwide Availability of Vafseo® (vadadustat) Across All IRC Dialysis Clinics

CAMBRIDGE, Mass. and FRANKLIN, Tenn., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impac...

Are there any supply chain, pricing, or reimbursement risks associated with scaling Vafseo® across all IRC clinics that could influence the stock's volatility? What is the expected market share gain for Vafseo® versus existing anemia treatments in the dialysis space, and how might that impact competitor valuations? How will the nationwide launch of Vafseo® affect Akebia Therapeutics' revenue forecasts and earnings guidance?
Symbol: AKBA
Product launch
21 days ago
Read more globenewswire

Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia

-Dabogratinib is the only oral FGFR3-selective inhibitor in clinical development for achondroplasia- -Initial results from safety sentinel cohort expected in 2H 2026- CARLSBAD, Calif., Aug. 21, 202...

When can we realistically expect safety sentinel cohort data and subsequent regulatory milestones, and how might those timelines impact the stock valuation? What is the potential market size and pricing power for the only oral FGFR3‑selective inhibitor in achondroplasia compared to existing off‑label therapies? How will the Phase 2 dosing of Dabogratinib affect Tyra's near‑term cash burn and runway?
Symbol: TYRA
Clinical trials
21 days ago
Read more prnewswire

First Nordic Drills 1.94 g/t Au over 21.5 m and 5.45 g/t Au over 4.6 m at Aida and Extends Gold Mineralization to over 2 km

TORONTO, Aug. 21, 2025 /PRNewswire/ - First Nordic Metals Corp. (the "Company" or "FNM") (TSX.V: FNM, FNSE: FNMC SDB, OTCQB: FNMCF, FRA: HEG0) is pleased to announce results to date (14 of 39 holes...

How does First Nordic’s current drilling performance compare to regional peers, and what does this mean for its competitive positioning and future financing opportunities? What is the market’s likely reaction to the extension of gold mineralization over more than 2 km in terms of valuation and required capital spending? How will the high‑grade drill intercepts at Aida affect First Nordic’s near‑term resource estimate and potential production forecasts?
Symbol: FNM
Mining
21 days ago
Read more prnewswire

Dynavax Announces Positive Topline Phase 1/2 Results Supporting Potential Best-in-Class Shingles Vaccine Profile

At all doses and formulations evaluated in Part 1 of the trial, Z-1018 was well-tolerated and demonstrated a favorable tolerability profile, including lower solicited local and systemic post-inject...

What market share potential does Z-1018 have given its tolerability advantage, and how might it impact competitive dynamics in the shingles vaccine space? What are the expected timelines for Phase 3 enrollment and potential FDA approval compared to Shingrix's pathway? How will the positive Phase 1/2 data affect Dynavax's valuation and short-term stock momentum?
Symbol: DNVX
Clinical trials
21 days ago
Read more prnewswire